1. Home
  2. DSP vs AGEN Comparison

DSP vs AGEN Comparison

Compare DSP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$12.85

Market Cap

275.0M

Sector

Technology

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$7.43

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSP
AGEN
Founded
1999
1994
Country
United States
United States
Employees
470
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.0M
274.8M
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
DSP
AGEN
Price
$12.85
$7.43
Analyst Decision
Strong Buy
Buy
Analyst Count
8
2
Target Price
$17.81
$14.50
AVG Volume (30 Days)
299.5K
1.8M
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
157.14
100.00
EPS
N/A
0.96
Revenue
$344,201,000.00
$42,877,086.00
Revenue This Year
$20.27
$107.63
Revenue Next Year
$16.88
N/A
P/E Ratio
N/A
$7.29
Revenue Growth
19.00
89.95
52 Week Low
$8.11
$2.71
52 Week High
$14.80
$8.85

Technical Indicators

Market Signals
Indicator
DSP
AGEN
Relative Strength Index (RSI) 54.44 62.66
Support Level $10.65 $3.09
Resistance Level $13.76 $8.78
Average True Range (ATR) 0.80 0.72
MACD 0.10 -0.13
Stochastic Oscillator 50.77 48.15

Price Performance

Historical Comparison
DSP
AGEN

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: